Published in Nat Rev Cardiol on May 14, 2013
Congenic fine-mapping identifies a major causal locus for variation in the native collateral circulation and ischemic injury in brain and lower extremity. Circ Res (2013) 1.68
Loss of interleukin-21 receptor activation in hypoxic endothelial cells impairs perfusion recovery after hindlimb ischemia. Arterioscler Thromb Vasc Biol (2015) 0.89
Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system. Biomaterials (2013) 0.87
Characterization of the arterial anatomy of the murine hindlimb: functional role in the design and understanding of ischemia models. PLoS One (2013) 0.84
Inhibition of Caspase-1 Activation in Endothelial Cells Improves Angiogenesis: A NOVEL THERAPEUTIC POTENTIAL FOR ISCHEMIA. J Biol Chem (2015) 0.84
Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine. Front Bioeng Biotechnol (2015) 0.84
Endothelial Msx1 transduces hemodynamic changes into an arteriogenic remodeling response. J Cell Biol (2015) 0.83
New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv Drug Deliv Rev (2014) 0.83
Therapeutic potential of sustained-release sodium nitrite for critical limb ischemia in the setting of metabolic syndrome. Am J Physiol Heart Circ Physiol (2015) 0.80
Therapeutic manipulation of angiogenesis with miR-27b. Vasc Cell (2015) 0.80
A novel molecule Me6TREN promotes angiogenesis via enhancing endothelial progenitor cell mobilization and recruitment. Sci Rep (2014) 0.79
CdGAP/ARHGAP31, a Cdc42/Rac1 GTPase regulator, is critical for vascular development and VEGF-mediated angiogenesis. Sci Rep (2016) 0.79
Computational Model of MicroRNA Control of HIF-VEGF Pathway: Insights into the Pathophysiology of Ischemic Vascular Disease and Cancer. PLoS Comput Biol (2015) 0.79
One-pot Synthesis of Elastin-like Polypeptide Hydrogels with Grafted VEGF-Mimetic Peptides. Biomater Sci (2014) 0.79
Mitochondrial Regulation of the Muscle Microenvironment in Critical Limb Ischemia. Front Physiol (2015) 0.79
Aligned-Braided Nanofibrillar Scaffold with Endothelial Cells Enhances Arteriogenesis. ACS Nano (2015) 0.78
Impaired compensation to femoral artery ligation in diet-induced obese mice is primarily mediated via suppression of collateral growth by Nox2 and p47phox. Am J Physiol Heart Circ Physiol (2015) 0.78
Improving the therapeutic efficacy of mesenchymal stromal cells to restore perfusion in critical limb ischemia through pulsed focused ultrasound. Sci Rep (2017) 0.77
Endothelial interleukin-21 receptor up-regulation in peripheral artery disease. Vasc Med (2015) 0.77
Systems biology of the microvasculature. Integr Biol (Camb) (2015) 0.77
A coupled model of neovessel growth and matrix mechanics describes and predicts angiogenesis in vitro. Biomech Model Mechanobiol (2014) 0.77
Transplantation of bradykinin-preconditioned human endothelial progenitor cells improves cardiac function via enhanced Akt/eNOS phosphorylation and angiogenesis. Am J Transl Res (2015) 0.77
Computational Network Model Prediction of Hemodynamic Alterations Due to Arteriolar Rarefaction and Estimation of Skeletal Muscle Perfusion in Peripheral Arterial Disease. Microcirculation (2015) 0.77
Hypoxia augments outgrowth endothelial cell (OEC) sprouting and directed migration in response to sphingosine-1-phosphate (S1P). PLoS One (2015) 0.76
In Silico Investigation of Angiogenesis with Growth and Stress Generation Coupled to Local Extracellular Matrix Density. Ann Biomed Eng (2015) 0.76
PADPIN: protein-protein interaction networks of angiogenesis, arteriogenesis, and inflammation in peripheral arterial disease. Physiol Genomics (2015) 0.76
Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics. Front Pharmacol (2015) 0.76
Heat therapy promotes the expression of angiogenic regulators in human skeletal muscle. Am J Physiol Regul Integr Comp Physiol (2016) 0.76
Diminished force production and mitochondrial respiratory deficits are strain-dependent myopathies of subacute limb ischemia. J Vasc Surg (2016) 0.76
GM-CSF treated F4/80+ BMCs improve murine hind limb ischemia similar to M-CSF differentiated macrophages. PLoS One (2014) 0.76
Formation of microvascular networks: role of stromal interactions directing angiogenic growth. Microcirculation (2014) 0.76
Cardiac Regeneration using Growth Factors: Advances and Challenges. Arq Bras Cardiol (2016) 0.75
Transplantation of bradykinin-preconditioned human endothelial progenitor cells improves cardiac function via enhanced Akt/eNOS phosphorylation and angiogenesis. Am J Transl Res (2015) 0.75
Elevated Levels of Adhesion Proteins Are Associated With Low Ankle-Brachial Index: Multi-Ethnic Study of Atherosclerosis. Angiology (2016) 0.75
TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE. Trans Am Clin Climatol Assoc (2016) 0.75
Integrin signaling in atherosclerosis. Cell Mol Life Sci (2017) 0.75
Cilostazol Improves Proangiogenesis Functions in Human Early Endothelial Progenitor Cells through the Stromal Cell-Derived Factor System and Hybrid Therapy Provides a Synergistic Effect In Vivo. Biomed Res Int (2016) 0.75
Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation. Front Physiol (2017) 0.75
Deficient CDKN2B Expression: A Double Hit for PAD. Circ Res (2016) 0.75
Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells. PLoS Comput Biol (2017) 0.75
Inhibition of PHD3 by salidroside promotes neovascularization through cell-cell communications mediated by muscle-secreted angiogenic factors. Sci Rep (2017) 0.75
Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent. Immunol Endocr Metab Agents Med Chem (2014) 0.75
Novel magnetic resonance imaging end points for physiologic studies in peripheral arterial disease: elegance versus practicality. Circ Cardiovasc Imaging (2015) 0.75
Vascular growth responses to chronic arterial occlusion are unaffected by myeloid specific focal adhesion kinase (FAK) deletion. Sci Rep (2016) 0.75
Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. Oncotarget (2017) 0.75
Deletion of TXNIP Mitigates High-Fat Diet-Impaired Angiogenesis and Prevents Inflammation in a Mouse Model of Critical Limb Ischemia. Antioxidants (Basel) (2017) 0.75
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg (2007) 14.17
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg (2000) 5.50
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet (1996) 4.32
Medical treatment of peripheral arterial disease and claudication. N Engl J Med (2001) 3.92
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet (2002) 3.31
Peripheral arterial disease. Lancet (2001) 2.96
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet (2011) 2.88
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82
A quantitative trait locus (LSq-1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia. Circulation (2008) 2.77
Medical treatment of peripheral arterial disease. JAMA (2006) 2.76
Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation (2002) 2.60
Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation (1995) 2.47
Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. Physiol Genomics (2007) 2.46
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation (2002) 2.39
Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol (2009) 2.31
Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol (2002) 2.21
Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler Thromb Vasc Biol (2006) 2.17
Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc Natl Acad Sci U S A (1990) 2.15
Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther (2008) 2.13
Angiogenesis: where do we stand now? Circulation (2005) 2.08
Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol (1999) 1.95
Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation (2004) 1.92
Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest (2000) 1.90
A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol (2008) 1.50
[Surgical treatment of peripheral circulation disorders]. Helv Chir Acta (1954) 1.47
Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med (2010) 1.45
Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet (1992) 1.44
Preclinical models of human peripheral arterial occlusive disease: implications for investigation of therapeutic agents. J Appl Physiol (1985) (2004) 1.43
Current status of cardiovascular gene therapy. Mol Ther (2007) 1.41
Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am J Physiol (1997) 1.37
Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol (2003) 1.33
A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res (2004) 1.32
P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation (2003) 1.31
Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet (2011) 1.26
Multiscale models of angiogenesis. IEEE Eng Med Biol Mag (2009) 1.26
Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation (2011) 1.25
Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther (2006) 1.22
Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg (2002) 1.21
Plasma nitrite response and arterial reactivity differentiate vascular health and performance. Nitric Oxide (2009) 1.20
The fate of patients with critical leg ischemia. Semin Vasc Surg (1999) 1.20
Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease. J Vasc Surg (2005) 1.18
Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther (2010) 1.16
Genetic background influences therapeutic effectiveness of VEGF. Biochem Biophys Res Commun (2003) 1.15
Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc Med (2007) 1.13
Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg (2006) 1.11
The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis, and inflammation in rat hindlimb ischemia. J Vasc Surg (2005) 1.11
Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg (2010) 1.10
Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Arterioscler Thromb Vasc Biol (2011) 1.10
Re-evaluating therapeutic neovascularization. J Mol Cell Cardiol (2004) 1.09
Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip Rev Syst Biol Med (2010) 1.06
Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg (2004) 1.05
De novo vasculogenesis in the heart. Cardiovasc Res (2003) 1.04
Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. J Appl Physiol (1985) (2011) 1.03
Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31. Am J Hum Genet (2002) 1.02
HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis (2004) 1.02
The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. J Thromb Haemost (2004) 1.00
A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol Ther (2011) 1.00
IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart. Am J Physiol Heart Circ Physiol (2001) 1.00
Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation (1999) 0.98
Lack of functional benefits following infrainguinal bypass in peripheral arterial occlusive disease patients. Vasc Med (2001) 0.98
Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. J Vasc Surg (2007) 0.96
Arteriogenesis, the good and bad of it. Cardiovasc Res (1999) 0.95
Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst Biol (2011) 0.94
The Basle longitudinal study: report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality. J Chronic Dis (1979) 0.94
Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery. Gene Ther (2013) 0.93
Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther (2009) 0.93
VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am J Physiol Heart Circ Physiol (2010) 0.93
Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiol Genomics (2009) 0.90
Gene therapy from the perspective of systems biology. Curr Opin Mol Ther (2010) 0.87
Adeno-associated virus serotype 9-mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind-limb ischemia in BALB/c mice. J Vasc Surg (2011) 0.84
Endothelial dysfunction--an obstacle of therapeutic angiogenesis. Ageing Res Rev (2009) 0.84
Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model. J Mol Med (Berl) (2005) 0.81